Your browser doesn't support javascript.
loading
Is Lymph Node Dissection Necessary During Radical Nephroureterectomy for Clinically Node-Negative Upper Tract Urothelial Carcinoma? A Multi-Institutional Study.
Lee, Hsiang-Ying; Chang, Chao-Hsiang; Huang, Chi-Ping; Yu, Chih-Chin; Lo, Chi-Wen; Chung, Shiu-Dong; Wu, Wei-Che; Chen, I-Hsuan Alan; Lin, Jen-Tai; Jiang, Yuan-Hong; Lee, Yu-Khun; Hsueh, Thomas Y; Chiu, Allen W; Chen, Yung-Tai; Lin, Chang-Min; Tsai, Yao-Chou; Chen, Wei-Chieh; Chiang, Bing-Juin; Huang, Hsu-Che; Chen, Chung-Hsin; Huang, Chao-Yuan; Wu, Chia-Chang; Lin, Wei Yu; Tseng, Jen-Shu; Ke, Hung-Lung; Yeh, Hsin-Chih.
Afiliação
  • Lee HY; Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
  • Chang CH; Department of Urology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
  • Huang CP; Department of Urology, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung, Taiwan.
  • Yu CC; Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
  • Lo CW; Department of Urology, China Medical University and Hospital, Taichung, Taiwan.
  • Chung SD; School of Medicine, China Medical University, Taichung, Taiwan.
  • Wu WC; Department of Urology, China Medical University and Hospital, Taichung, Taiwan.
  • Chen IA; School of Medicine, China Medical University, Taichung, Taiwan.
  • Lin JT; Division of Urology, Department of Surgery, Taipei Tzu Chi Hospital, The Buddhist Medical Foundation, New Taipei City, Taiwan.
  • Jiang YH; School of Medicine, Buddhist Tzu Chi University, Hualien, Taiwan.
  • Lee YK; Division of Urology, Department of Surgery, Taipei Tzu Chi Hospital, The Buddhist Medical Foundation, New Taipei City, Taiwan.
  • Hsueh TY; Graduate Program in Biomedical Informatics, College of Informatics, Yuan-Ze University, Chung-Li, Taiwan.
  • Chiu AW; Division of Urology, Department of Surgery, Far Eastern Memorial Hospital, New Taipei City, Taiwan.
  • Chen YT; Division of Urology, Department of Surgery, Far Eastern Memorial Hospital, New Taipei City, Taiwan.
  • Lin CM; Institute of Biomedical Engineering, National Taiwan University, Taipei, Taiwan.
  • Tsai YC; Division of Urology, Department of Surgery, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.
  • Chen WC; Division of Urology, Department of Surgery, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.
  • Chiang BJ; Department of Urology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation and Tzu Chi University, Hualien, Taiwan.
  • Huang HC; Department of Urology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation and Tzu Chi University, Hualien, Taiwan.
  • Chen CH; Division of Urology, Department of Surgery, Taipei City Hospital Renai Branch, Taipei, Taiwan.
  • Huang CY; Department of Urology, School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
  • Wu CC; College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
  • Lin WY; Department of Urology, Taiwan Adventist Hospital, Taipei, Taiwan.
  • Tseng JS; Department of Urology, Taiwan Adventist Hospital, Taipei, Taiwan.
  • Ke HL; Department of Urology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
  • Yeh HC; Department of Urology, Taipei Medical University Hospital, Taipei, Taiwan.
Front Oncol ; 12: 791620, 2022.
Article em En | MEDLINE | ID: mdl-35574295
ABSTRACT

Purpose:

This study aimed to compare the oncological outcomes of patients with upper tract urothelial carcinoma (UTUC) without clinical lymph node metastasis (cN0) undergoing lymph node dissection (LND) during radical nephroureterectomy (NU).

Methods:

From the updated data of the Taiwan UTUC Collaboration Group, a total of 2726 UTUC patients were identified. We only include patients with ≥ pT2 stage and enrolled 658 patients. The Kaplan-Meier estimator and Cox proportional hazards model were used to analyze overall survival (OS), cancer-specific survival (CSS), disease-free survival (DFS), and bladder recurrence-free survival (BRFS) in LND (+) and LND (-) groups.

Results:

A total of 658 patients were included and 463 patients without receiving LND and 195 patients receiving LND. From both univariate and multivariate survival analysis, there are no significant difference between LND (+) and LND (-) group in survival rate. In LND (+) group, 18.5% patients have pathological LN metastasis. After analyzing pN+ subgroup, it revealed worse CSS (p = 0.010) and DFS (p < 0.001) compared with pN0 patients.

Conclusions:

We found no significant survival benefit related to LND in cN0 stage, ≥ pT2 stage UTUC, irrespective of the number of LNs removed, although pN+ affected cancer prognosis. However, from the result of pN (+) subgroup of LND (+) cohort analysis, it may be reasonable to not perform LND in patients with cT2N0 stage due to low positive predictive value of pN (+). In addition, performing LND may be considered for ureter cancer, which tends to cause lymphatic and hematogenous tumor spreading. Further large prospective studies are needed to validate our findings.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article